Cargando…
A Five‐Year Study of the Efficacy of Purified CD34+ Cell Therapy for Angiitis‐Induced No‐Option Critical Limb Ischemia
Angiitis‐induced critical limb ischemia (AICLI) patients constitute a remarkable proportion of no‐option critical limb ischemia (CLI) patients. Stem cell therapy has become an innovative and promising option for no‐option CLI patients. As one of these promising stem cell therapies, purified CD34+ ce...
Autores principales: | Fang, Yuan, Wei, Zheng, Chen, Bin, Pan, Tianyue, Gu, Shiyang, Liu, Peng, Guo, Daqiao, Xu, Xin, Jiang, Junhao, Yang, Jue, Shi, Zhenyu, Zhu, Ting, Shi, Yun, Liu, Yifan, Dong, Zhihui, Fu, Weiguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090512/ https://www.ncbi.nlm.nih.gov/pubmed/29709112 http://dx.doi.org/10.1002/sctm.17-0252 |
Ejemplares similares
-
Purified CD34(+) cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-Month results of a prospective randomised single-blinded non-inferiority trial
por: Dong, Zhihui, et al.
Publicado: (2018) -
Autologous Stem Cells Transplantation for No-Option Angiitis-Induced Critical Limb Ischemia: Recurrence and New Lesion
por: Liu, Hao, et al.
Publicado: (2022) -
Autologous peripheral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia: 10-year management experience
por: Fang, Gang, et al.
Publicado: (2020) -
Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia
por: Jiang, Xiaolang, et al.
Publicado: (2021) -
Three‐year outcomes of peripheral blood mononuclear cells vs purified CD34
(+) cells in the treatment of angiitis‐induced no‐option critical limb ischemia and a cost‐effectiveness assessment: A randomized single‐blinded noninferiority trial
por: Liu, Hao, et al.
Publicado: (2021)